RBC
PVLA

Roble Belko & Company’s Palvella Therapeutics PVLA Stock Holding History

Roble Belko & Company’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-26
Closed -$7K – 360
2019
Q1 		$7K Hold
26
– – ﹤0.01% 252
2018
Q4 		$5K Hold
26
– – ﹤0.01% 253
2018
Q3 		$12K Hold
26
– – ﹤0.01% 206
2018
Q2 		$10K Hold
26
– – ﹤0.01% 233
2018
Q1 		$14K Hold
26
– – 0.01% 207
2017
Q4 		$16K Buy
+26
New +$12.1K 0.01% 191

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Roble Belko & Company's PVLA Position: Q2 2019 in Review

Roble Belko & Company sold out of Palvella Therapeutics (PVLA) in Q2 2019, closing a stake of 26 shares — an estimated $7K sold.

Roble Belko & Company first reported a position in PVLA in Q4 2017 and held it in 6 quarters. The position peaked at $16K in Q4 2017. 93 funds tracked by Wall St. Rank hold PVLA as of Q2 2019.

  • Roble Belko & Company reported no remaining Palvella Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Roble Belko & Company sold 26 Palvella Therapeutics shares in Q2 2019, an estimated $7K.
  • Roble Belko & Company first reported a position in Palvella Therapeutics in Q4 2017 and held it in 6 quarters.
  • Roble Belko & Company's Palvella Therapeutics position peaked at $16K in Q4 2017.
  • 93 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2019.

Based on Roble Belko & Company's 13F filing for Q2 2019, filed 13 Aug 2019.